Mary Kay Ladone - 02 Jun 2025 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
02 Jun 2025
Net transactions value
$0
Form type
4
Filing time
04 Jun 2025, 21:30:00 UTC
Previous filing
16 May 2025
Next filing
14 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ladone Mary Kay Director 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM /s/ Anthony D'Adamio, Attorney-in-Fact 04 Jun 2025 0001760737

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +26,493 +50% $0.000000 78,981 02 Jun 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -26,493 -100% $0.000000 0 02 Jun 2025 Class A Common Stock 26,493 Direct F1, F2
transaction BVS Restricted Stock Units Award $0 +32,282 $0.000000 32,282 03 Jun 2025 Class A Common Stock 32,282 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs vested on June 2, 2025.
F3 The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.